BridgeMD
Adapting the length of antibiotics for respiratory tract infections in primary care.
EU CTIS ID: 2024-518683-13-00
What this study is testing
To assess the overall assessment of the clinical efficacy at day 14
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ranging from 18 to 75 years of age
- Acute lower Respiratory Tract Infection or acute bacterial rhinosinusitis
- GPs deem a beta-lactam therapy for at least seven days is necessary
You likely can't join if
- Respiratory Tract Infections different from a lower RTI or acute rhinosinusitis
- Inability/unable to understand and/or take part in the clinical trial
- Currently participating in another clinical trial
- Previously participated in the STORM study
- Active neoplasia
- Terminal illness
See the full eligibility criteria
- Age ranging from 18 to 75 years of age
- Acute lower Respiratory Tract Infection or acute bacterial rhinosinusitis
- GPs deem a beta-lactam therapy for at least seven days is necessary
- Respiratory Tract Infections different from a lower RTI or acute rhinosinusitis
- Inability/unable to understand and/or take part in the clinical trial
- Currently participating in another clinical trial
- Previously participated in the STORM study
- Active neoplasia
- Terminal illness
- Institutionalized patient
- Inability to understand and/or participate in the clinical trial
- The doctor decides not to give an antibiotic for this RTI
- Patients with suspected septicaemia, based on the Quick SOFA scale; patients with two or more of the following criteria must be excluded: a) respiratory rate ≥22 breaths/minute; b) systolic blood pressure <100 mm Hg, and/or c) altered mental status with a Glasgow score <15)
- Patients with a severe community-acquired pneumonia, based on the CRB65 scale: patients with any of the following criterion must be excluded: a) confusion; b) respiratory rate ≥30 breaths/minute; c) systolic blood pressure <90 mm Hg or diastolic ≤60 mm Hg; and/or d) age ≥65 years
- Patients with COPD who have taken four or more antibiotic courses in the previous year, presence of significant bronchiectasis, and/or isolation of Pseudomonas in a previous sputum culture
- Patients with reported allergy to beta-lactams
- Patients who have taken an antibiotic in the previous two weeks
- A working diagnosis of a non-infective disorder, such as heart failure, pulmonary embolus, oesophageal reflux
- Immunocompromised patients, such as HIV infection, patients taking immunosuppressive treatment, antineoplastic therapy, or systemic corticosteroids
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.